Merck's Keytruda sales rose 17.2% YoY to $7.43 billion. Find out why MRK stock's strong fundamentals and high dividend yield ...

The Shanghai-based biotech could receive up to $2.7 billion in milestone payments depending on Merck’s progress with the drug across multiple indications. Merck’s Keytruda accounted for $21.6 ...

Merck and BioNTech are buying Chinese biotechs to gain PD-(L)1/VEGF bispecifics ... tapped by Merck & Co. in a separate collaboration. 6. Merck KGaA's phase 3 rare tumor trial hits goal, teeing ...

Ascentage Pharma (6855.HK) is a global, integrated biopharmaceutical company engaged in discovering, developing and commercializing therapies to address global unmet medical needs primarily in ...

AK_ATM_1.8.0_1111.7z是AK原版大气层1.8.0个人整合包1111版 （1）和AK原版大气层1.7.1相比。 （1.9）1111版更新ovlSysmodules--v1.3.2，SaltyNX--v1.0.5，NX-Activity-Log--v1.5.1，更新FPSLocker锁帧补丁。 （1.8）1107版更新 ...

Treyarch has once again enabled legacy XP tokens to work with today's Call of Duty: Black Ops 6 update 1.62 download.

Warzone update 1.061 brings Season One and Black Ops 6 integration to the battle royale game. Read on for everything new.

Merck said on Tuesday a study showed its injectable version of cancer drug Keytruda was not inferior to the currently ...

Merck has signed a licensing agreement worth up to $3.3 billion with Shanghai-based LaNova Medicines to develop, make and ...

today announced that Merck has entered into an exclusive global license to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova.

Merck & Co. Inc. has in-licensed Lanova Medicines Ltd.’s PD-1/VEGF bispecific antibody LM-299 in a deal worth up to $2.7 billion in a move to bolster its Keytruda (pembrolizumab) fortress. Under terms ...

We recently compiled a list of the Jim Cramer Talked About These 11 Stocks Recently. In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against the other ...